189 related articles for article (PubMed ID: 34718844)
1. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
[TBL] [Abstract][Full Text] [Related]
2. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
Berz AM; Santana JG; Iseke S; Gross M; Pekurovsky V; Laage Gaupp F; Savic LJ; Borde T; Gottwald LA; Boustani AM; Gebauer B; Lin M; Zhang X; Schlachter T; Madoff DC; Chapiro J
J Vasc Interv Radiol; 2022 Jul; 33(7):764-774.e4. PubMed ID: 35346859
[TBL] [Abstract][Full Text] [Related]
3. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?
Savic LJ; Doemel LA; Schobert IT; Montgomery RR; Joshi N; Walsh JJ; Santana J; Pekurovsky V; Zhang X; Lin M; Adam L; Boustani A; Duncan J; Leng L; Bucala RJ; Goldberg SN; Hyder F; Coman D; Chapiro J
Radiology; 2020 Sep; 296(3):575-583. PubMed ID: 32633675
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
5. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
6. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
[TBL] [Abstract][Full Text] [Related]
7. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.
Gaba RC; Khabbaz RC; Muchiri RN; Morrison JD; Elkhadragy L; Totura WM; Samuelson JP; Whiteley HE; Deaton RL; Nguyen PL; Sverdlov M; Johnson JJ; van Breemen RB; Lokken RP
Drug Deliv Transl Res; 2022 May; 12(5):1105-1117. PubMed ID: 33861419
[TBL] [Abstract][Full Text] [Related]
8. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.
Savic LJ; Schobert IT; Peters D; Walsh JJ; Laage-Gaupp FM; Hamm CA; Tritz N; Doemel LA; Lin M; Sinusas A; Schlachter T; Duncan JS; Hyder F; Coman D; Chapiro J
Clin Cancer Res; 2020 Jan; 26(2):428-438. PubMed ID: 31582517
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment.
Borde T; Laage Gaupp F; Geschwind JF; Savic LJ; Miszczuk M; Rexha I; Adam L; Walsh JJ; Huber S; Duncan JS; Peters DC; Sinusas A; Schlachter T; Gebauer B; Hyder F; Coman D; van Breugel JMM; Chapiro J
J Vasc Interv Radiol; 2020 Oct; 31(10):1706-1716.e1. PubMed ID: 32684417
[TBL] [Abstract][Full Text] [Related]
11. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model.
Kim D; Lee JH; Moon H; Seo M; Han H; Yoo H; Seo H; Lee J; Hong S; Kim P; Lee HJ; Chung JW; Kim H
Theranostics; 2021; 11(1):79-92. PubMed ID: 33391462
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.
Elkhadragy L; Khabbaz RC; Muchiri RN; Totura WM; Samuelson JP; Whiteley HE; van Breemen RB; Lokken RP; Gaba RC
J Vasc Interv Radiol; 2022 Oct; 33(10):1213-1221.e5. PubMed ID: 35850455
[TBL] [Abstract][Full Text] [Related]
14. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
15. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
16. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
[TBL] [Abstract][Full Text] [Related]
18. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
Liu X; Xie Y; Qi X; Xu K
J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
[TBL] [Abstract][Full Text] [Related]
20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
